Author | Elsas, Maria Ignez Capella Gaspar | |
Author | Vargaftig, B. B. | |
Author | Xavier-Elsas, Pedro Paulo | |
Access date | 2013-01-31T18:58:11Z | |
Available date | 2013-01-31T18:58:11Z | |
Document date | 2000 | |
Citation | ELSAS, Maria Ignez Capella Gaspar; VARGAFTIG, B. B.; XAVIER-ELSAS, Pedro Paulo. Do glucocorticoids enhance eosinopoiesis? Trends in Pharmacological Sciences, Amsterdam, v. 21, n. 11, p. 417-420, Nov. 2000. | pt_BR |
ISSN | 0165-6147 | |
URI | https://www.arca.fiocruz.br/handle/icict/6286 | |
Language | por | pt_BR |
Publisher | Elsevier Science | pt_BR |
xmlui.metadata.dc.relation.isbasedon | Barnes, P.J. (1999) Anti-inflammatory actions
of glucocorticoids: molecular mechanisms.
Clin. Sci. 94, 557–572. | pt_BR |
xmlui.metadata.dc.relation.isbasedon | Giembycz, M.A. and Lindsay, M.A. (1999)
Pharmacology of the eosinophil. Pharmacol.
Rev. 51, 213–339. | pt_BR |
xmlui.metadata.dc.relation.isbasedon | O’Byrne, P.M. and Wood, L. (1999)
Interleukin-5 and allergic inflammation.
Clin. Exp. Allergy 29, 573–575. | pt_BR |
xmlui.metadata.dc.relation.isbasedon | Gaspar Elsas, M.I. et al. (2000) Upregulation
by glucocorticoids of responses to eosinopoietic
cytokines in bone-marrow from normal
and allergic mice. Br. J. Pharmacol. 129,
1453–1552. | pt_BR |
xmlui.metadata.dc.relation.isbasedon | Dorman, S.C. et al. (2000) Corticosteroid
enhancement of IL-5-dependent eosinophil
progenitor differentiation in vitro. Am. J.
Resp. Crit. Care Med. 161, A540. | pt_BR |
xmlui.metadata.dc.relation.isbasedon | Wiegers, G.J. and Reul, J.M.H.M. (1998)
Induction of cytokine receptors by glucocorticoids:
functional and pathological significance.
Trends Pharmacol. Sci. 19, 317–321. | pt_BR |
xmlui.metadata.dc.relation.isbasedon | Agarwal, S.K. and Marshall, G.D. (1998)
Glucocorticoid-induced type 1/type 2 cytokine
alterations in humans: a model for stressrelated
immune dysfunction. J. Interferon
Cytokine Res. 18, 1059–1068. | pt_BR |
xmlui.metadata.dc.relation.isbasedon | Dekruyff, R. et al. (1998) Corticosteroids
enhance the capacity of macrophages to
induce Th2 cytokine synthesis in CD41
lymphocytes by inhibiting IL-12 production.
J. Immunol. 160, 2231–2237. | pt_BR |
xmlui.metadata.dc.relation.isbasedon | Erb, K.J. (1999) Atopic disorders: a default
pathway in the absence of infection?
Immunol. Today 20, 317–322. | pt_BR |
xmlui.metadata.dc.relation.isbasedon | Elenkov, I.J. and Chrousos, G.P. (1999)
Stress hormones, Th1/Th2 patterns, pro/antiinflammatory
cytokines and susceptibility to
disease. Trends Endocrinol. Metab. 10, 359–368. | pt_BR |
xmlui.metadata.dc.relation.isbasedon | Sanderson, C.J. et al. (1998) Interleukin-5. In
Cytokines (Mire-Sluys, A., ed.), pp. 69–85,
Academic Press. | pt_BR |
xmlui.metadata.dc.relation.isbasedon | Slovick, F.T. et al. (1985) Modulation of in
vitro eosinophil progenitors by hydrocortisone:
role of accessory cells and interleukins. Blood
66, 1072–1079. | pt_BR |
xmlui.metadata.dc.relation.isbasedon | Butterfield, J.H. et al. (1986) Effects of
glucocorticoids on eosinophil colony growth.
J. Allergy Clin. Immunol. 78, 450–457. | pt_BR |
xmlui.metadata.dc.relation.isbasedon | Barr, D.D. et al. (1987) Stimulation of
human eosinophilopoiesis by hydrocortisone
in vitro. Acta Haematol. 77, 20–24. | pt_BR |
xmlui.metadata.dc.relation.isbasedon | O’Byrne, P.M. et al. (1999) Interaction
between haemopoietic regulation and airway
inflammation. Clin. Exp. Allergy 29,
27–32. | pt_BR |
xmlui.metadata.dc.relation.isbasedon | Das, A.M. et al. (1997) A novel murine
model of allergic inflammation to study the
effect of dexamethasone on eosinophil
recruitment. Br. J. Pharmacol. 121, 97–104. | pt_BR |
xmlui.metadata.dc.relation.isbasedon | Palframan, R.T. et al. (1998) Mechanisms
of acute eosinophil mobilization from the
bone marrow stimulated by interleukin-5:
the role of specific adhesion molecules and
phosphatidylinositol 3-kinase. J. Exp. Med.
188, 1621–1632. | pt_BR |
xmlui.metadata.dc.relation.isbasedon | Wilckens, T. (1995) Glucocorticoids and
immune function: physiological relevance and
pathogenic potential of hormonal dysfunction.
Trends Pharmacol. Sci. 16, 193–197. | pt_BR |
xmlui.metadata.dc.relation.isbasedon | Siqueira, A. et al. (1997) A new murine
model of pulmonary eosinophilic hypersensitivity.
Contribution to experimental
asthma. J. Allergy Clin. Immunol. 100, 383–388. | pt_BR |
xmlui.metadata.dc.relation.isbasedon | Dhabhar, F. et al. (2000) Stress-induced
enhancement of skin immune function:
a role for g interferon. Proc. Natl. Acad. Sci.
U. S. A. 97, 2846–2851. | pt_BR |
Rights | restricted access | pt_BR |
Title | Do glucocorticoids enhance eosinopoiesis? | pt_BR |
Type | Article | pt_BR |
DOI | 10.1016/s0165-6147(00)01568-6 | |
Abstract | It is well established that glucocorticoids (GCs) are beneficial for the treatment of many inflammatory and allergic diseases, including asthma 1. , in which tissue infiltration by eosinophil leukocytes plays a major role in pathogenesis. Eosinophils are produced and stored in the bone marrow, to be subsequently released into the circulation and recruited, under the influence of chemotactic factors, into inflammatory sites, where they can contribute to tissue damage by secreting toxic proteins, inflammatory mediators and cytokines 2. . Many studies have shown that GCs inhibit the production of a subset of cytokines [interleukin 5 (IL-5), granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-3] that can contribute to eosinophilic inflammation by stimulating the production of eosinophils in the bone marrow (eosinopoiesis). These same cytokines increase the survival of mature eosinophils that are recruited to the tissues and promote their activation in a variety of ways. The ability to suppress synthesis of the eosinopoietic cytokines is thought to underlie the ability of GCs to reduce blood and tissue eosinophilia 2. , 3. . In addition, because GCs have been shown to inhibit many of the effects of these cytokines on mature eosinophils, it is often assumed that GCs will always antagonize the effects of IL-5, GM-CSF and IL-3, regardless of the maturation stage of the target cell. However, as we argue below, the relationship between GCs and eosinopoietic cytokines includes synergistic as well as antagonistic aspects, and might depend on the maturation stage of the target cells. In this context, recent evidence from our own 4. and other laboratories 5. that GCs can actually potentiate the eosinopoietic actions of GM-CSF and IL-5 in the bone marrow is likely to raise important questions. Here, we suggest that these findings have implications for therapy with GCs and discuss how these paradoxical findings relate to differences between eosinophils in bone marrow and other sites. | |
Affilliation | Fundação Oswaldo Cruz. Instituto Fernandes Figueira. Departamento de Pesquisa. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Institut National de la Santé et de la Recherche Médicale. Institut Pasteur. Unité de Pharmacologie Cellulaire. Paris, France. | pt_BR |
Affilliation | Universidade Federal do Rio de Janeiro. Instituto de Microbiologia. Departamento de Microbiologia. Rio de Janeiro, RJ, Brasil. | pt_BR |
Subject | Glucocorticoids (GCs) | |
Subject | Treatment of many inflammatory | |
Subject | Allergic diseases | |
Subject | Eosinophils | |
DeCS | Antiinflamatórios | pt_BR |
DeCS | Eosinófilos | pt_BR |
DeCS | Glucocorticóides | pt_BR |
DeCS | Hematopoese | pt_BR |
Embargo date | 2030-12-31 | |